Skip to main content

Table 3 Correlation between AURKA intensity and clinical features based on GSE136755

From: Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors

Parameter Characteristic No. patients (%) AURKA intensity Statistics P value
Gender Female 26 (40.0) 6.19 ± 0.97 t = − 1.458 0.150
Male 39 (60.0) 6.63 ± 1.47   
Age < 68 31 (47.7) 6.28 ± 1.17 t = 1.022 0.311
≥ 68 34 (52.3) 6.62 ± 1.41   
Location* Stomach 43 (66.2) 6.14 ± 1.25  F = 4.306 0.018
Non-stomach 16 (24.6) 6.95 ± 0.99   
Metastasis 6 (9.2) 7.39 ± 1.74   
Risk* High 17 (26.2) 7.54 ± 1.30  F = 11.898 < 0.001
Intermediate 9 (13.8) 5.75 ± 0.54   
Low 22 (33.8) 6.06 ± 0.94   
Very low 11 (16.9) 5.66 ± 0.74   
Stage* IV 9 (13.8) 7.94 ± 1.63  F = 10.686 < 0.001
III 9 (13.8) 6.85 ± 0.89   
II 8 (12.3) 7.13 ± 1.55   
I 39 (60.0) 5.89 ± 0.84   
Mutation Sensitive 56 (86.2) 6.39 ± 1.21  F = 2.541 0.087
Resistance 7 (10.8) 7.33 ± 1.84   
 N/A 2 (3.1) 5.29 ± 0.20   
Mutation Sensitive 56 (88.9) 6.39 ± 1.21 t = 1.814 0.075
Resistance 7 (11.1) 7.33 ± 1.84   
  1. *P < 0.05 was considered statistically significant